The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The burden of metastatic melanoma (mM): Treatment patterns, healthcare use, and costs.
C. Reyes
Employment or Leadership Position - Genentech
Stock Ownership - Roche
S. DaCosta Byfield
Consultant or Advisory Role - Genentech
S. Satram-Hoang
Consultant or Advisory Role - Genentech
A. H. Teitelbaum
Consultant or Advisory Role - Genentech